BioNTech’s Founders Prepare Their Exit as the Market Awaits a Pipeline Verdict
Published on 07/27/2026 at 03:02 | Redaktion boerse-global.de
Investors in BioNTech endured a rough end to the week, with shares sliding 2.66 percent to close at €78.75 on Friday. The stock now sits roughly a quarter below its 52-week high of €105.80, reached back in January, and the drift lower has left it trading beneath both its 50-day moving average of €79.39 and its 200-day average of €84.63. The Relative Strength Index at 43.2 points to neutral-to-slightly-bearish sentiment — hardly a vote of confidence for a company sitting on a war chest of roughly €16.8 billion.
That cash pile is at the heart of a growing debate among shareholders. One camp argues that BioNTech’s formidable balance sheet alone justifies a higher valuation. The other side counters that the real test lies in the oncology pipeline, where uncertainty remains high. The 30-day annualized volatility of around 25 percent underscores just how divided the market is on where the stock should trade.
A Founder-Led Spin-Out Takes Centre Stage
Adding to the uncertainty is a leadership transition that is already set in stone. CEO U?ur ?ahin and Chief Medical Officer Ă–zlem TĂĽreci will depart by the end of this year to establish a new mRNA-focused biotechnology venture. BioNTech will contribute certain mRNA technologies and rights to the spin-out in exchange for a minority stake. The idea is to let the parent company concentrate fully on its late-stage oncology pipeline while maintaining a scientific link to its mRNA roots.
Investors are still waiting for the binding contracts governing that spin-out, which were originally expected by mid-2026. The delay has only added to the sense of limbo surrounding the stock. With the founders’ departure now a matter of months away, the question of who will succeed them — and what strategic direction they will take — is becoming an increasingly urgent topic in investor forums.
Should investors sell immediately? Or is it worth buying BioNTech?
Pumitamig and the Race to 15 Phase-3 Trials
BioNTech has set an ambitious target: 15 ongoing Phase-3 oncology studies by the end of 2026. The most prominent candidate in that push is Pumitamig, also known as BNT327, a bispecific antibody targeting PD-L1 and VEGF-A that is being developed in partnership with Bristol Myers Squibb. The drug is currently running in five potentially registration-enabling trials, including studies in non-small cell lung cancer and triple-negative breast cancer.
Beyond oncology, the company is also advancing its infectious disease portfolio. The mRNA-based HIV vaccine candidate BNT168 is expected to make progress in clinical testing this month. These efforts are part of a broader pivot away from the shrinking COVID-19 vaccine revenue stream that once defined BioNTech’s fortunes.
All Eyes on August 4
The next major catalyst arrives on August 4, when BioNTech is scheduled to report its second-quarter 2026 earnings. The numbers will give investors their best look yet at how quickly the oncology pipeline is maturing and whether the company’s cash position remains as robust as it appears. For a stock that has been trading in a narrow range between roughly €78 and €82 over the past week, the earnings release could provide the breakout — or breakdown — that traders have been waiting for.
BioNTech at a turning point? This analysis reveals what investors need to know now.
In the near term, attention is likely to focus on the support zone around €78. With no major clinical data releases expected before the earnings date, positioning ahead of the report will probably dominate trading. The central question remains whether the market will start pricing in a “catalyst-rich” second half of 2026 or continue to fixate on the fading pandemic-era revenue. The answer may begin to take shape as soon as next week.
Ad
BioNTech Stock: New Analysis - 27 July
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
